Alector, Inc. (ALEC) stock declined over -0.49% intraday to trade at $10.16 a share on NASDAQ. The stock opened with a gain of 0.30% at $10.01 and touched an intraday high of $10.445, falling -0.49% against the last close of $10.21. The stock went to a low of $9.84 during the session.
Number of Shares
Cash Flow per Share
Free Float in %
Sales or Revenue207.08 Million
5Y Sales Change246.30%
Fiscal Year Ends2021-12-30
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
Alector, Inc. (NASDAQ: ALEC) stock price is $10.16 as of the last check on Thursday, June 30. During the trading session, ALEC stock reached the peak price of $10.445 while $9.84 was the lowest point it dropped to.
The NASDAQ listed ALEC is part of Biotechnology industry that operates in the broader Health Care sector. Alector, Inc. , a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases.
Dr. Robert Paul M.D., Ph.D.
Ms. Linda M. Rubinstein
Interim CFO, Principal Financial Officer & Principal Accounting Officer
Mr. Brian Sander J.D., Ph.D.
Dr. Tillman Ulf Gerngross Ph.D.
Co-Founder & Chairman
ALEC stock traded closed the last session at $10.16, which is $-0.05 or -0.49% lower than its previous close of $10.21. ALEC's current trading price is 35.47% lower than its 52-week high of $43.32 where as its distance from 52-week low of 7.50% is -76.55%.
Number of ALEC employees currently stands at -. ALEC operates from 131 Oyster Point Boulevard, Suite 600, South San Francisco, CA 94080, United States.
Official Webiste of $ALEC is: https://www.alector.com
ALEC could be contacted at ALEC operates from 131 Oyster Point Boulevard, Suite 600, South San Francisco, CA 94080, United States, or at phone #415 231 5660 and can also be accessed through its website.
ALEC stock volume for the day was 455,151 shares while in the previous session number of ALEC shares traded was 443,409 . The average number of ALEC shares traded daily for last 3 months was 702 Thousands.
The percentage change in ALEC stock occurred in the recent session was -0.49% while the dollar amount for the price change in ALEC stock was $-0.05.
In the recent session, the day high for ALEC stock was $10.445 while the low for ALEC stock touched on the day was $9.84.
The market value of ALEC currently stands at 820.12 Million with its latest stock price at $10.16 and 82.1 Million of its shares outstanding.